Effective experimental design is foundational to smarter, faster drug development, ensuring every sample, assay, and insight generated directly contributes to your scientific objectives and delivers evidence that informs optimal therapeutic program strategy.
As a leader innovating multi-omics approaches to uncover dynamic, functional biology behind disease and drug response, Sapient brings unique expertise to craft bespoke studies that can answer even the most complex biological questions.
Whether your goals are exploratory discovery, target or biomarker validation, or clinical trial optimization, we work collaboratively with your team to align our omics data services in ways that will meaningfully inform and advance your pipeline.
We work to align your biological question with available samples and intended downstream decisions to ensure your study delivers the statistical power, biological depth, and data robustness needed to maximize discovery, translational, or clinical value.
Our engagements begin with collaborative review and refinement of the biological question you are seeking to answer, whether it be mechanistic, diagnostic, predictive, or translational in nature.
We can recommend the appropriate workflows and techniques within our broad omics data services portfolio to achieve these objectives. This could include discovery or targeted analyses of proteins, metabolites, lipids, and cytokines, or starting with an exploration of data within our DynamiQ clinical-molecular database to refine hypotheses and guide further testing frameworks.
With advanced sample accessioning workflows, we can rapidly intake client-provided samples in virtually any matrix, from plasma and tissue to saliva, CSF, tears, urine, stool, dried blood spots, and cells. We provide sample preparation guidance to accommodate unique sample characteristics, including for low-input samples.
It is also possible to tap into Sapient's DynamiQ Plasma database, which includes >67,000 pre-characterized human plasma samples linked with multi-omics and matched clinical data, to build a virtual cohort from this diverse longitudinal dataset. And, if you need access to human tissue samples with specific disease context, we offer streamlined access to thousands of annotated FFPE tumors and normal tissue via our DynamiQ Tumor-Tissue virtual biobank.
Our goal is to ensure that the omics data we produce is both scientifically robust and fit‑for‑purpose for the decisions you need to make and the regulatory expectations of your study.
For example, early‑stage discovery studies benefit from our broad, unbiased profiling capabilities that deliver scalable reproducibility and the statistical depth needed for robust discovery and hypothesis-building. Later‑stage clinical studies require heightened precision and methodological rigor, which we can deliver through high-sensitivity, quantitative targeted assays with analytical validation based on appropriate context of use (COU) statements.
We help define the COU upfront and, across all studies, apply comprehensive QC frameworks and platform‑level controls designed to ensure high-quality, biologically interpretable results.
Our interpretation framework is grounded in the deep biocomputational expertise of our data science team, who have extensive experience analyzing and integrating large-scale omics datasets. And, as the only multi-omics provider with a population-scale molecular-clinical database, DynamiQ™, we offer a unique advantage to both analyze data generated from your samples and validate the findings in independent real-world cohorts.
This allows us to move beyond lists of differential features to integrated biological narratives that explain why pathways are activated, how phenotypes emerge, and what the implications are for drug development. We offer standard interpretation packages for relevant omics study to provide this biological contextualization, and can further tailor bespoke analyses to delve deeper into specific characterization and modeling using DynamiQ.
Find more details on our approaches, experience, and how we’ll work together.
Too often, traditional biomarker studies rely on narrow analyte panels or static snapshots that miss the dynamic reality of human biology. Sapient was built to change that.
We focus on delivering actionable omics, not just datasets. Combining next‑generation, high‑resolution omics platforms with our longitudinal, population‑scale molecular-clinical database, DynamiQ™, we are able to assay and interpret dynamic protein, metabolite, lipid, and cytokine biomarkers – the ultimate effectors of health and disease states – at scale.
By bridging the gap between inferred and functional biology, we help you decipher the heterogeneity in disease and patient response, integrating multiple layers of molecular data for more certainty through mechanistic context, more confidence with reproducible evidence, and faster decision-making with outputs made to act on.
Genomics offers critical information on inherited risk and mutational drivers, but actual disease biology and drug response are largely governed by dynamic protein and metabolite activity. By directly measuring these molecular layers, we can capture the functional state of a system: pathway activation, post‑translational modifications, resistance biology, immune states, and disease phenotypes. Such data often reveal mechanisms invisible to DNA or RNA alone and help to advance targets or biomarkers with true biological relevance.
Whether your program needs novel differentiation or mechanistic grounding, we can deliver those high‑impact insights with speed. Below are just a few example use cases of where can can add value in your drug development pipeline:
Sapient has supported numerous pharma, biotech, academic centers, and precision oncology platforms in rapidly identifying targets, validating biomarkers, refining trial designs, and uncovering responder biology.
Examples include:
Explore more case studies and data published in collaboration with our clients.
No problem. Our scientists are here to help refine your biological question, assess available samples, and clarify the decision(s) you need to make. From there, we recommend the optimal combination of nontargeted and/or targeted omics data services, provide sample access options if needed, and determine the level of analytical rigor required based on the context of use.
Yes, focused pilot studies are available to quickly assess feasibility, generate early insights, and guide larger follow‑on programs. This helps build confidence in the robustness of our approaches for your full discovery, translational, and clinical programs.
We view ourselves as an extension of your internal team and bring together a cross-functional group of experts tailored to address your study’s biological complexity.
This typically includes a Principal Investigator to act as your scientific lead and a Project Manager to oversee timelines and study logistics, supported by analytical chemists expert in our proteomics, metabolomics, or NULISA platforms and data scientists from our biocomputational team to handle omics data services related to dataset integration and interpretation.
Connect with our scientists to discuss your project or the biological questions you want to answer. We’re here to help you design and execute a high-impact study.
"*" indicates required fields
